Bluehole New Consumption Publishes a Feature Story on Recent Vaping Regulation Updates
4.11.2021 05:45:00 EET | Business Wire | Press release
China’s leading vaping media, Bluehole New Consumption, today published a feature story on recent vaping regulation updates in the UK, the US and Malaysia. As vaping accepted by more and more health regulators, the industry will witness a more concentrated and standardized market.
Here below is the full article in English:
On October 29, 2021, the U.K government agency, Medicines and Healthcare Products Regulatory Agency (MHRA) announced that NHS could soon prescribe e-cigarettes to help tobacco smokers quit, inviting e-cigarette manufacturers to submit products to undergo the same approval process as prescribed medicines. It could make England the first country to prescribe medicinally licensed e-cigarettes. Under such a circumstance, “A medically licensed e-cigarette would have to pass even more rigorous safety checks than those required for them to be sold commercially,” according to BBC.
On the same day, the Malaysian government announced to impose excise duty on nicotine vapor products. The managing director of British America Tobacco (BAT) Malaysia, Nedal Salem, said this indicates the Malaysian government is looking to legalize nicotine vapor products: “Regulation will not only allow vape users access to reduced-risk alternatives to smoking, but also ensure the products used are compliant to quality and safety standards.”
Meanwhile, in October, the U.S Food and Drug Administration (FDA) has granted marketing orders for Vuse Solo and accompanying tobacco flavored e-liquid pods, making it the first set of e-cigarette authorized for sale by the FDA.
From the UK to Malaysia and the U.S, E-cigarette is accepted by more and more health regulators around the world as an effective harm-reduction tool to improve public health.
As BAT Malaysia states, regulation could positively accelerate healthy development of the vaping industry for setting higher quality requirements and safety standards for products. Moreover, regulation measures, such as the marketing authorization and prescription evaluation, could be deemed the regulators’ acknowledgement of the products’ public health benefits.
Besides, Mitch Zeller, director of the FDA Center for Tobacco Products, said that “many of the tobacco product reviews are in final stages,” at a virtual conference hosted by the Food and Drug Law Institute on October 27. However, the agency so far has only authorized three products for their substantial evidence of harm reduction while issuing marketing denial orders for 200 thousand products.
Vuse is currently in a lead position to pass the Premarket Tobacco Product Applications (PMTA) process. It showcases that the FDA (and perhaps other regulators) is more likely to trust and approve products made by market leaders for assured public health benefits and reliability proved by sufficient scientific data.
The FDA’s rigorous requirements for products are also applied to manufacturers. SMOORE, the world’s largest vaping manufacturer, is the strategic supplier of VUSE. It features PMTA-related non-clinical evaluation capabilities, including physical testing, chemical testing and health risk assessment. Moreover, SMOORE’s CNAS tests have also expanded to 134.
As the regulatory framework outlines a higher entry barrier for the industry, the global vaping industry will witness a more standardized and concentrated market where industry leaders, such as BAT and SMOORE, will further strengthen their leading positions. Meanwhile, the whole industry and the supply chain will benefit from such a well-regulated and standardized market in turn.
To read the original article, please visit: https://www.bluehole.com.cn/news/detail/47350
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103006380/en/
Contact information
Bluehole New Consumption Contact Info:
(+86)18612693874
CHEN ZHONG
SMOOR
Frankie Chen
(+86)13530848319
frankie.chen@smoorecig.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OCTO and Volkswagen Group Info Services AG Form Partnership for Fleet Data Integration24.3.2026 11:00:00 EET | Press release
OCTO, a leading company in the field of telematics, data analytics and AI-driven solutions for insurance and fleet management, announces a strategic partnership with Volkswagen Group Info Services AG. The goal of this cooperation is to expand data solutions for fleet operators by directly integrating vehicle data from the brands Volkswagen Passenger Cars, Volkswagen Commercial Vehicles, Škoda, Seat, Cupra and Audi. Through this partnership, OCTO gains direct access to vehicle data from fleet vehicles of these six Volkswagen brands. This enables innovative mobility services for fleet managers, including maintenance management, theft protection, damage management, fraud detection, driving behavior analysis, activity reports, e-mobility management, corporate car sharing, and many other functions. These services utilize data such as mileage, fuel consumption, EV status, warning messages, and other parameters, without requiring additional hardware installations. Innovation Through Data Inte
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 10:30:00 EET | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information and to view the Company’s abstract, visit the AACR Annual Meeting website. About ASTX295 ASTX295 is a potent, highly selective, potentially best-in-class MDM2 antagonist that has completed a phase I study (NCT03975387) in over 100 patients with advanced solid tumors. Rationally designed to exhibit a
Vonage and ServiceNow Expand their Partnership24.3.2026 10:20:00 EET | Press release
Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vonage integration, calls can automatically trigger incident categorisation, initiate ServiceNow Flow Designer subflows, and update issue resolution data in real time, helping to reduce ma
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 10:00:00 EET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 08:00:00 EET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
